There is no such thing as approximate time of survival for atrophic gastritis. Because atrophic gastritis after active treatment, generally does not affect the patient’s life expectancy.
Atrophic gastritis refers to atrophy of the gastric mucosal epithelium and the intrinsic glands of the gastric mucosa or accompanied by pyloric glandular metaplasia and intestinal glandular metaplasia. If active measures are taken to treat the disease and regular follow-up examinations are conducted, the patient can usually live as long as a normal person, and there is a risk of cancer, but the chance is low.
Atrophic gastritis may become cancerous if you don’t take active steps to treat it and pay attention to your daily diet. This condition can affect life expectancy, and the chance of cancer can be more than 20%. Once cancer occurs, it will pose a threat to the patient’s life and the patient’s quality of life will be reduced.
Atrophic gastritis with Helicobacter pylori infection can be given quadruple therapy, such as omeprazole, metronidazole, tetracycline, colloidal bismuth pectin and other medications, which can prevent the further development of gastric mucosal atrophy and intestinal metaplasia.
Patients with atrophic gastritis are advised to seek timely medical attention and follow medical advice.